About
LUNAC Therapeutics is a University of Leeds spin-out developing first-in-class oral and intravenous small-molecule inhibitors of activated Factor XII (FXIIa) to prevent pathological thrombosis while avoiding the bleeding risk of current anticoagulants.
Explore LUNAC Therapeutics's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.